Real-life effect of long-acting β2-agonist withdrawal in patients with controlled step 3 asthma

Sunny Jabbal; Arvind Manoharan; William Anderson; Joseph Lipworth; Brian Lipworth

doi:10.1016/j.anai.2016.07.022

Real-life effect of long-acting β2-agonist withdrawal in patients with controlled step 3 asthma

Sunny Jabbal, Arvind Manoharan, William Anderson, Joseph Lipworth (Lead / Corresponding author), Brian Lipworth (Lead / Corresponding author)

Research output: Contribution to journal › Letter › peer-review

4 Citations (Scopus)

Abstract

Approximately 45% of patients with asthma in the United Kingdom are receiving step 3 or higher therapy,1 most commonly inhaled corticosteroids (ICSs) and long-acting β2-agonists (LABAs). The 2016 Global Initiative for Asthma (GINA) guidelines propose a cycle of assessment, stepwise adjustment of treatment, and review of response to ascertain the lowest treatment to achieve control.2 In addition, the US Food and Drug Administration advocates stopping use of LABAs once asthma control is achieved and maintained and switching to ICS monotherapy.

Original language	English
Pages (from-to)	430-431
Number of pages	2
Journal	Annals of Allergy, Asthma and Immunology
Volume	117
Issue number	4
Early online date	9 Aug 2016
DOIs	https://doi.org/10.1016/j.anai.2016.07.022
Publication status	Published - Oct 2016

Access to Document

10.1016/j.anai.2016.07.022

Cite this

@article{f42f630ef7204f28b7bc1090a92c4be2,

title = "Real-life effect of long-acting β2-agonist withdrawal in patients with controlled step 3 asthma",

abstract = "Approximately 45% of patients with asthma in the United Kingdom are receiving step 3 or higher therapy,1 most commonly inhaled corticosteroids (ICSs) and long-acting β2-agonists (LABAs). The 2016 Global Initiative for Asthma (GINA) guidelines propose a cycle of assessment, stepwise adjustment of treatment, and review of response to ascertain the lowest treatment to achieve control.2 In addition, the US Food and Drug Administration advocates stopping use of LABAs once asthma control is achieved and maintained and switching to ICS monotherapy.",

author = "Sunny Jabbal and Arvind Manoharan and William Anderson and Joseph Lipworth and Brian Lipworth",

note = " Dr Anderson reported receiving honorarium and travel grants from AstraZeneca. Dr Lipworth reported receiving consulting fees from Chiesi, Dr Reddy's Laboratories, Cipla, and Sandoz, speaker fees from Meda, and grant support from Meda, Teva, and Roche. ",

year = "2016",

month = oct,

doi = "10.1016/j.anai.2016.07.022",

language = "English",

volume = "117",

pages = "430--431",

journal = "Annals of Allergy, Asthma and Immunology",

issn = "1081-1206",

publisher = "American College of Allergy, Asthma and Immunology",

number = "4",

}

TY - JOUR

T1 - Real-life effect of long-acting β2-agonist withdrawal in patients with controlled step 3 asthma

AU - Jabbal, Sunny

AU - Manoharan, Arvind

AU - Anderson, William

AU - Lipworth, Joseph

AU - Lipworth, Brian

N1 - Dr Anderson reported receiving honorarium and travel grants from AstraZeneca. Dr Lipworth reported receiving consulting fees from Chiesi, Dr Reddy's Laboratories, Cipla, and Sandoz, speaker fees from Meda, and grant support from Meda, Teva, and Roche.

PY - 2016/10

Y1 - 2016/10

N2 - Approximately 45% of patients with asthma in the United Kingdom are receiving step 3 or higher therapy,1 most commonly inhaled corticosteroids (ICSs) and long-acting β2-agonists (LABAs). The 2016 Global Initiative for Asthma (GINA) guidelines propose a cycle of assessment, stepwise adjustment of treatment, and review of response to ascertain the lowest treatment to achieve control.2 In addition, the US Food and Drug Administration advocates stopping use of LABAs once asthma control is achieved and maintained and switching to ICS monotherapy.

AB - Approximately 45% of patients with asthma in the United Kingdom are receiving step 3 or higher therapy,1 most commonly inhaled corticosteroids (ICSs) and long-acting β2-agonists (LABAs). The 2016 Global Initiative for Asthma (GINA) guidelines propose a cycle of assessment, stepwise adjustment of treatment, and review of response to ascertain the lowest treatment to achieve control.2 In addition, the US Food and Drug Administration advocates stopping use of LABAs once asthma control is achieved and maintained and switching to ICS monotherapy.

U2 - 10.1016/j.anai.2016.07.022

DO - 10.1016/j.anai.2016.07.022

M3 - Letter

C2 - 27519578

SN - 1081-1206

VL - 117

SP - 430

EP - 431

JO - Annals of Allergy, Asthma and Immunology

JF - Annals of Allergy, Asthma and Immunology

IS - 4

ER -

Real-life effect of long-acting β2-agonist withdrawal in patients with controlled step 3 asthma

Abstract

Access to Document

Fingerprint

Cite this